Clene reports Q1 net loss of $11.8M, cash $18.4M; ALS data milestones expected mid-2023

Clene Inc.

Net loss $11.8M ($0.15/sh) vs $13.4M ($0.21/sh) in Q1 2022; R&D $7.4M, G&A $3.4M.
Cash and marketable securities $18.4M as of Mar 31, expected to fund ops into Q3 2023.
ALS survival benefit data from HEALEY and RESCUE-ALS trials presented at AAN; biomarker/long-term survival data expected mid-2023.
Appointed Benjamin Greenberg, M.D., as Head of Medical; entered $25M equity facility with Lincoln Park.
MS regulatory discussions anticipated in Q4 2023; advancing partnership opportunities.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clene Inc. reported first quarter ended March 31, 2023 results: net income $11.8 million, EPS $0.15 per share.

Period: first quarter ended March 31, 2023
Net income: $11.8 million
EPS: $0.15 per share
Result: reported results

Exact text from the filing

Clene reported a net loss of $11.8 million , or $0.15 per share, for the quarter ended March 31, 2023, compared to a net loss of $13.4 million , or $0.21 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-014227

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.